The discipline of medicinal chemistry is devoted to the discovery and development of new agents for treating diseases. This lab, biomedicinal chemistry, is focusing on discovering a drug target and a (natural or synthetic) lead compound interacting with the target, thus providing molecular information for rational drug development.

Selected Publications

1. Hong S, Yum S, Yoo HJ, Kang S, Yoon JH, Min D, Kim YM, Jung Y. Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis.Mol Pharm. 2012 May 7;9(5):1310-9.
2. Lee Y, Kim J, Kim H, Kang S, Yoon JH, Kim DD, Kim YM, Jung Y. N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties. J Pharm Sci. 2012 May;101(5):1831-42.
3. Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis. EurJ Med Chem. 2012 Feb;48:36-44.
4. Jung Y*, Kim YM. What should be considered on design of a colon-specific prodrug? Expert Opin Drug Deliv. 2010 Feb;7(2):245-58.
5. Yum S, Choi J, Hong S, Park MH, Lee J, Ha NC, Jung Y*.Hyperoxia attenuates the inhibitory effect of nitric oxide donors on HIF prolyl-4-hydroxylase-2: Implication on discriminative effect of nitric oxide on HIF prolyl-4-hydroxylase-2 and collagen prolyl-4-hydroxylase. Biochem Pharmacol. Sep 1;82(5):485-90, 2011,